Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcomaParag P. Patwardhan, Gary K. Schwartz|Oncotarget|2015Cited by 112